Such limitations are due to a lack of samples from patients treated with HSP90 inhibitors, mainly as a consequence of the toxicity profiles of clinically tested inhibitors and the paucity of response to treatment by patients with lung adenocarcinoma. Here, HSP90AB1 is linked to lung adenocarcinoma.